GlassScriptPhysician profile
William T Christensen
NPI 1316020332
$2,801.21
in general payments reported to CMS, 2019-2025
31 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $174 · 2021: $359 · 2022: $436 · 2023: $276 · 2024: $285 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $669.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $326.19 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $266.46 | 2019-2025 | Evenity, Prolia, Prolia |
| Amarin Pharma, INC. | $236.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $166.15 | 2019-2025 | Farxiga |
| Pfizer INC. | $146.33 | 2019-2024 | |
| Abbvie INC. | $114.73 | 2019-2022 | |
| Astellas Pharma US INC | $84.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $75.18 | 2019 | |
| Lilly USA, LLC | $55.69 | 2022-2025 | Kisunla |
| Exact Sciences Corporation | $53.21 | 2024 | |
| Axogen | $49.85 | 2025 | |
| Inspire Medical Systems, INC. | $48.89 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.61 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $43.11 | 2025 | Apollo Esg System |
| E.R. Squibb & Sons, L.L.C. | $40.61 | 2019-2022 | |
| Abbott Laboratories | $35.77 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $30.25 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $29.75 | 2020-2024 | |
| Dynavax Technologies Corporation | $23.56 | 2022 | |
| Gilead Sciences, INC. | $23.41 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.99 | 2019 | |
| Sumitomo Pharma America, INC. | $22.42 | 2025 | Gemtesa |
| Eisai INC. | $19.13 | 2021 | |
| Insmed, INC. | $17.41 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.32 | 2022 | |
| Medtronic Vascular, INC. | $15.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.64 | 2023 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $13.55 | 2022 | |
| Allergan, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.